Related Experiment Video
Updated: Jul 9, 2025
A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
Published on: September 15, 2018
PCSK9 Inhibitors - A New Hope for Dyslipidemia in HIV
Sanjana Datla1,2, Sundeep Kumar1,2
1From the University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH.
Insights
HIV patients face rising cardiovascular disease and dyslipidemia risks due to treatments and the virus itself. Proprotein convertase subtilisin/kexin type 9 inhibitors show promise for managing lipids in this population.
Area of Science:
- Cardiology
- Infectious Diseases
- Pharmacology
Background:
- Cardiovascular disease (CVD) prevalence is increasing among individuals with human immunodeficiency virus (HIV).
- Both HIV infection and antiretroviral therapy (ART) independently elevate the risk of dyslipidemia.
- Statins are the primary treatment for dyslipidemia in HIV patients but have limitations due to drug interactions and adverse events.
Purpose of the Study:
- To evaluate the efficacy of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors as an early intervention for dyslipidemia in the HIV population.
- To compare the lipid-lowering effects of PCSK9 inhibitors with traditional statin therapy in HIV patients.
Main Methods:
- Review of preliminary clinical trial data on PCSK9 inhibitors in HIV patients with dyslipidemia.
- Analysis of lipid profiles, including low-density lipoprotein (LDL) cholesterol and other atherogenic lipids.
Main Results:
- Preliminary trials indicate PCSK9 inhibitors significantly reduce LDL cholesterol and atherogenic lipid levels.
- PCSK9 inhibitors demonstrate a promising safety and efficacy profile in managing dyslipidemia.
Conclusions:
- PCSK9 inhibitors represent a viable and effective therapeutic option for dyslipidemia in HIV patients.
- Early consideration of PCSK9 inhibitors alongside statins may improve cardiovascular risk management in this vulnerable population.
Abstract:
Cardiovascular disease has become increasingly prevalent in the HIV population. Antiretroviral therapy and HIV itself independently increase the risk of dyslipidemia. While statins are currently the predominant therapy to treat dyslipidemia in HIV patients, drug-drug interactions and adverse drug events can limit their use. Proprotein convertase subtilisin/kexin type 9 inhibitors have shown promising results in preliminary trials by significantly reducing low density lipoprotein and other atherogenic lipid levels. They should be considered as an early intervention alongside statins in HIV patients with dyslipidemia.
More Related Videos
07:29Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
08:45LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
Published on: November 17, 2018
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:10Retrovirus Life Cycles